share_log

Insiders Were the Biggest Winners as Anhui Huaren Health Pharmaceutical Co., Ltd.'s (SZSE:301408) Market Cap Grew by CN¥508m Last Week

内部者は安徽省華仁健康医薬品株式会社(SZSE:301408)の時価総額が先週 CN¥50800万 増加したことで最大の勝者となりました

Simply Wall St ·  12/13 07:52

Key Insights

  • Anhui Huaren Health Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion
  • The largest shareholder of the company is Jiale He with a 50% stake
  • Institutions own 13% of Anhui Huaren Health Pharmaceutical

To get a sense of who is truly in control of Anhui Huaren Health Pharmaceutical Co., Ltd. (SZSE:301408), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Clearly, insiders benefitted the most after the company's market cap rose by CN¥508m last week.

Let's take a closer look to see what the different types of shareholders can tell us about Anhui Huaren Health Pharmaceutical.

big
SZSE:301408 Ownership Breakdown December 12th 2024

What Does The Institutional Ownership Tell Us About Anhui Huaren Health Pharmaceutical?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Anhui Huaren Health Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Anhui Huaren Health Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.

big
SZSE:301408 Earnings and Revenue Growth December 12th 2024

We note that hedge funds don't have a meaningful investment in Anhui Huaren Health Pharmaceutical. The company's largest shareholder is Jiale He, with ownership of 50%. This implies that they have majority interest control of the future of the company. Alibaba Health Information Technology Limited is the second largest shareholder owning 7.5% of common stock, and Jialun He holds about 6.9% of the company stock. Jialun He, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

Insider Ownership Of Anhui Huaren Health Pharmaceutical

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our most recent data indicates that insiders own the majority of Anhui Huaren Health Pharmaceutical Co., Ltd.. This means they can collectively make decisions for the company. That means they own CN¥3.0b worth of shares in the CN¥5.3b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

The general public, who are usually individual investors, hold a 17% stake in Anhui Huaren Health Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

Our data indicates that Private Companies hold 5.2%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Public Company Ownership

It appears to us that public companies own 7.5% of Anhui Huaren Health Pharmaceutical. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Anhui Huaren Health Pharmaceutical has 2 warning signs we think you should be aware of.

Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする